Dong Liang to Biological Availability
This is a "connection" page, showing publications Dong Liang has written about Biological Availability.
Connection Strength
0.906
-
Gao S, Siddiqui N, Etim I, Du T, Zhang Y, Liang D. Developing nutritional component chrysin as a therapeutic agent: Bioavailability and pharmacokinetics consideration, and ADME mechanisms. Biomed Pharmacother. 2021 Oct; 142:112080.
Score: 0.204
-
Awosemo O, Neelakantan H, Watowich S, Ma J, Wu L, Chow DS, Liang D. Development & validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. J Pharm Biomed Anal. 2021 Sep 10; 204:114255.
Score: 0.202
-
Gao S, Bell EC, Zhang Y, Liang D. Racial Disparity in Drug Disposition in the Digestive Tract. Int J Mol Sci. 2021 Jan 21; 22(3).
Score: 0.196
-
Robinson K, Mock C, Liang D. Pre-formulation studies of resveratrol. Drug Dev Ind Pharm. 2015; 41(9):1464-9.
Score: 0.134
-
John MK, Xie H, Bell EC, Liang D. Development and pharmacokinetic evaluation of a curcumin co-solvent formulation. Anticancer Res. 2013 Oct; 33(10):4285-91.
Score: 0.118
-
Du T, Sun R, Etim I, Zheng Z, Liang D, Hu M, Gao S. Age-and Region-Dependent Disposition of Raloxifene in Rats. Pharm Res. 2021 Aug; 38(8):1357-1367.
Score: 0.051